NextCure, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from NextCure, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.7 times its market value (net cash). Higher than 94% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-49.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 73% of Healthcare companies in United States.
Cash Cushion Ratio
1.7× cashCash, after subtracting all debt, is 1.7 times its market value (net cash).
Higher than 94% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
NextCure, Inc. made a loss over the last year. NextCure, Inc. owes $0.46 for every $1 it owns. NextCure, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossNextCure, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.78The share price is 1.78 times NextCure, Inc.'s book value per share, lower than 62% of Healthcare companies in United States.
Market cap
$22 MThe total market value of all of NextCure, Inc.'s shares at today's price (share price × number of shares), smaller than 81% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$12 MWhat NextCure, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.65Net worth divided by the number of shares. The share price of $4.72 is 1.8 times this, which is the P/B above.
Return on equity (ROE)
-204.6%NextCure, Inc. lost 204.6% of its shareholders' money over the last year, lower than 85% of Healthcare companies in United States.
Owes vs Owns
0.46×NextCure, Inc. owes $0.46 for every $1 it owns (low), higher than 53% of Healthcare companies in United States.
Dividend yield
NoneNextCure, Inc. does not currently pay a dividend.
Profit growth
LossNextCure, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashNextCure, Inc. held $37 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For NextCure, Inc.: $22 M ÷ $12 M (30 Jun 2026) = 1.8.
What is NextCure, Inc.'s return on equity?
NextCure, Inc. lost 204.6% of its shareholders' money over the last year, lower than 85% of Healthcare companies in United States.
How much does NextCure, Inc. owe compared with what it owns?
NextCure, Inc. owes $0.46 for every $1 it owns (low), higher than 53% of Healthcare companies in United States.
Does NextCure, Inc. pay a dividend?
No. NextCure, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.